An improved synthetic process for gefitinib;
吉非替尼的合成工艺改进
Antiproliferative effects on non-small cell lung cancer cells by combining Tamoxifen and Gefitinib;
联合应用三苯氧胺和吉非替尼对NSCLC细胞的抗增殖效应
Advance in research of sunitinib,a multitargeted receptor tyrosine kinase inhibitor;
多靶点酪氨酸激酶抑制剂舒尼替尼的研究进展
AIM To evaluate the pharmacodynamics and pharmacokinetics of SHR115723 in comparison with those of sunitinib in vitro and in vivo,to determine the prospects of SHR115723 for new drug development.
目的对SHR115723进行初步体外和体内药效学、药动学研究,并与舒尼替尼进行比较,以了解SHR115723新药开发的潜力。
Effects of Cetuximab Combined Erlotinib on Proliferation of Human Hepatocellular Carcinoma Cell Lines HepG2 and Bel-7402;
西妥昔单抗联合厄洛替尼对人肝癌细胞的体外抑制作用
Preliminary Results of Erlotinib Concomitant with Radiation Therapy for Non-small Cell Lung Cancer Patients with Multiple Brain Metastases;
厄洛替尼联合全脑放射治疗非小细胞肺癌多发脑转移的初步观察
New drug for non-small cell lung cancer target therapy-erlotinib;
非小细胞肺癌靶向治疗新药——厄洛替尼
Efficacy and safety of Imatinib for Ph positive patients of chronic myeloid leukemia;
伊马替尼治疗Ph染色体阳性慢性粒细胞白血病的临床观察
Establishment of an Imatinib Resistance Cell Line K562R and Its Resistant Principia;
体外诱导K562细胞伊马替尼耐药及其机理的初步探讨
Imatinib mesylate combined with hematopiotic stem cell transplantation for chronic myloid leukemia;
伊马替尼联合造血干细胞移植治疗慢性粒细胞白血病